• Explore /
  • Poster
  • / Real-world (RW) survival and outcomes with androgen receptor pathway inhibitor (ARPI) –doublet therapy in patients (pts) with de novo metastatic castration-sensitive prostate cancer (mCSPC).

Real-world (RW) survival and outcomes with androgen receptor pathway inhibitor (ARPI) –doublet therapy in patients (pts) with de novo metastatic castration-sensitive prostate cancer (mCSPC).

Abstract Poster

Authors

null

Joshua Parrish

Section of Urology, Durham VA Health Care System, Durham, NC

Joshua Parrish , Thomas J. Polascik , Agnes Hong , Nader N. El-Chaar , Amanda Marie De Hoedt , Janet Kim , Claire Trustram Eve , Maelys Touya , Krishnan Ramaswamy , Lin Gu , Stephen J. Freedland

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2024 ASCO Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session A: Prostate Cancer

Track

Prostate Cancer - Advanced,Prostate Cancer - Localized

Sub Track

Therapeutics

Citation

J Clin Oncol 42, 2024 (suppl 4; abstr 145)

DOI

10.1200/JCO.2024.42.4_suppl.145

Abstract #

145

Poster Bd #

F16

Abstract Disclosures

Similar Posters

First Author: Daniel Joseph Khalaf

Poster

2021 Genitourinary Cancers Symposium

Survival outcomes in patients with metastatic castration-sensitive prostate cancer (mCSPC): A real-world evidence study.

Survival outcomes in patients with metastatic castration-sensitive prostate cancer (mCSPC): A real-world evidence study.

First Author: Stephen J. Freedland

First Author: Umang Swami

First Author: Andrew W Hahn